News

Targeting IL-4 and IL-13 signaling with dupilumab has demonstrated significant reductions in total and food-specific IgE in pediatric AD populations.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on Biofrontera’s sNDA for Ameluz PDT in superficial BCC, 52-week data on rezpegaldesleukin for AD, the FDA's latest iPLEDGE REMS updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

PDPA’s 2025 survey, led by president Jamie Restivo, PA-C, reveals dermatology PA pay trends, productivity bonuses, benefits gaps, and satisfaction drivers shaping retention.

Highlighting conditions like lichen planus, which has no FDA-approved treatments, Lio underscores why clinicians must be comfortable prescribing beyond the label.

As we celebrate Valentine's Day, Mona Shahriari, MD, FAAD; Neal Bhatia, MD; Peter Lio, MD; Lisa Swanson, MD; Lawrence Schachner, MD; Julie Karen, MD; and Glynis Ablon, MD, FAAD, share why they love dermatology.

Investigators identified overlap between the blood immune profiles of patients with depression and inflammatory skin diseases, highlighting the Th2 axis as a potential treatment target.

Des Fernandes, MBBCh, FRCS (Edin), pioneered microneedling as a safe skin regeneration therapy, demonstrating collagen gains and improved scars when paired with vitamins A and C.

The 2026 meeting emphasized integrating cutting-edge medical therapies with aesthetic strategies to address both disease control and quality of life.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

Advances in stem cells, exosomes, biomaterials, and RNA technologies are expanding therapeutic options beyond traditional wound-based remodeling.

At a recent IMCAS symposium with Merz Aesthetics, Bianca Viscomi, MD, revealed how menopause and skin collide through collagen loss, confidence dips, and multimodal fixes.

This issue highlights clinical insights relevant to inflammatory conditions in diverse populations, emphasizing practical strategies for everyday practice.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

DISCREET phase 3 research shows oral apremilast eases genital psoriasis symptoms, improving itch, clearance, and sexual quality of life through 32 weeks.

Cheri Frey, MD, shares skin of color anti-aging strategies—pigment-first planning, safer lasers/peels, and techniques to prevent PIH.

This review of the latest dermatological studies includes insights on lichen planus in family members, "washcloth withdrawal," the use of shiitake mushroom extract in dermatology, and more.

The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with atopic dermatitis receive systemic corticosteroids.

FDA eases iPLEDGE REMS for isotretinoin acne care, allowing some at-home pregnancy tests and fewer lockouts to reduce administrative burden.

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.